|
Synonyms: AQW 051 | AQW-051 | VQW 765 | VQW-765 | VQW765
Compound class:
Synthetic organic
Comment: AQW051 is an α7 nicotinic acetylcholine receptor (nAChR) partial agonist from Novartis that was proposed as an oral treatment for cognitive deficits in schizophrenia, Alzheimer's, and Parkinson's diseases [1,3]. The structure was first disclosed during the March 2014 ACS meeting. AQW051 was later re-named as VQW-765 having been licensed to Vanda Pharmaceuticals.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| No information available. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT01474421 | Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease | Phase 2 Interventional | Novartis | 5 | |
| NCT04800237 | Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety | Phase 2 Interventional | Vanda Pharmaceuticals | ||
| NCT07221578 | Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder | Phase 3 Interventional | Vanda Pharmaceuticals | ||